Simon Finch1, Melissa J McDonnell2, Hani Abo-Leyah1, Stefano Aliberti3, James D Chalmers1. 1. 1 Tayside Respiratory Research Group, University of Dundee, Ninewells Hospital and Medical School, Dundee, United Kingdom. 2. 2 Department of Respiratory Medicine, Galway University Hospitals, Galway, Ireland; and. 3. 3 Department of Health Science, University of Milan-Bicocca, Pneumology Clinic, San Gerardo Hospital, Monza, Italy.
Abstract
RATIONALE: Eradication and suppression of Pseudomonas aeruginosa is a key priority in national guidelines for bronchiectasis and is a major focus of drug development and clinical trials. An accurate estimation of the clinical impact of P. aeruginosa in bronchiectasis is therefore essential. METHODS: Data derived from 21 observational cohort studies comparing patients with P. aeruginosa colonization with those without it were pooled by random effects meta-analysis. Data were collected for key longitudinal clinical outcomes of mortality, hospital admissions, exacerbations, and lung function decline, along with cross-sectional outcomes such as quality of life. MEASUREMENTS AND MAIN RESULTS: In the aggregate, the included studies comprised 3,683 patients. P. aeruginosa was associated with a highly significant and consistent increase in all markers of disease severity, including mortality (odds ratio [OR], 2.95; 95% confidence interval [CI], 1.98-4.40; P < 0.0001), hospital admissions (OR, 6.57; 95% CI, 3.19-13.51; P < 0.0001), and exacerbations (mean difference, 0.97/yr; 95% CI, 0.64-1.30; P < 0.0001). The patients with P. aeruginosa also had worse quality of life on the basis of their St. George's Respiratory Questionnaire results (mean difference, 18.2 points; 95% CI, 14.7-21.8; P < 0.0001). Large differences in lung function and radiological severity were also observed. The definitions of colonization were inconsistent among the studies, but the findings were robust regardless of the definition used. CONCLUSION: P. aeruginosa is associated with an approximately threefold increased risk of death and an increase in hospital admissions and exacerbations in adult bronchiectasis.
RATIONALE: Eradication and suppression of Pseudomonas aeruginosa is a key priority in national guidelines for bronchiectasis and is a major focus of drug development and clinical trials. An accurate estimation of the clinical impact of P. aeruginosa in bronchiectasis is therefore essential. METHODS: Data derived from 21 observational cohort studies comparing patients with P. aeruginosa colonization with those without it were pooled by random effects meta-analysis. Data were collected for key longitudinal clinical outcomes of mortality, hospital admissions, exacerbations, and lung function decline, along with cross-sectional outcomes such as quality of life. MEASUREMENTS AND MAIN RESULTS: In the aggregate, the included studies comprised 3,683 patients. P. aeruginosa was associated with a highly significant and consistent increase in all markers of disease severity, including mortality (odds ratio [OR], 2.95; 95% confidence interval [CI], 1.98-4.40; P < 0.0001), hospital admissions (OR, 6.57; 95% CI, 3.19-13.51; P < 0.0001), and exacerbations (mean difference, 0.97/yr; 95% CI, 0.64-1.30; P < 0.0001). The patients with P. aeruginosa also had worse quality of life on the basis of their St. George's Respiratory Questionnaire results (mean difference, 18.2 points; 95% CI, 14.7-21.8; P < 0.0001). Large differences in lung function and radiological severity were also observed. The definitions of colonization were inconsistent among the studies, but the findings were robust regardless of the definition used. CONCLUSION:P. aeruginosa is associated with an approximately threefold increased risk of death and an increase in hospital admissions and exacerbations in adult bronchiectasis.
Authors: Emily Henkle; Timothy R Aksamit; Alan F Barker; Jeffrey R Curtis; Charles L Daley; M Leigh Anne Daniels; Angela DiMango; Edward Eden; Kevin Fennelly; David E Griffith; Margaret Johnson; Michael R Knowles; Amy Leitman; Philip Leitman; Elisha Malanga; Mark L Metersky; Peadar G Noone; Anne E O'Donnell; Kenneth N Olivier; Delia Prieto; Matthias Salathe; Byron Thomashow; Gregory Tino; Gerard Turino; Susan Wisclenny; Kevin L Winthrop Journal: Chest Date: 2017-05-05 Impact factor: 9.410
Authors: Micheál Mac Aogáin; Jayanth Kumar Narayana; Pei Yee Tiew; Nur A'tikah Binte Mohamed Ali; Valerie Fei Lee Yong; Tavleen Kaur Jaggi; Albert Yick Hou Lim; Holly R Keir; Alison J Dicker; Kai Xian Thng; Akina Tsang; Fransiskus Xaverius Ivan; Mau Ern Poh; Martina Oriano; Stefano Aliberti; Francesco Blasi; Teck Boon Low; Thun How Ong; Brian Oliver; Yan Hui Giam; Augustine Tee; Mariko Siyue Koh; John Arputhan Abisheganaden; Krasimira Tsaneva-Atanasova; James D Chalmers; Sanjay H Chotirmall Journal: Nat Med Date: 2021-04-05 Impact factor: 53.440
Authors: Simone K Visser; Peter T P Bye; Greg J Fox; Lucy D Burr; Anne B Chang; Chien-Li Holmes-Liew; Paul King; Peter G Middleton; Graeme P Maguire; Daniel Smith; Rachel M Thomson; Enna Stroil-Salama; Warwick J Britton; Lucy C Morgan Journal: Lung Date: 2019-11-05 Impact factor: 2.584
Authors: Alanna R Condren; Lisa Juliane Kahl; Gabriela Boelter; George Kritikos; Manuel Banzhaf; Lars E P Dietrich; Laura M Sanchez Journal: ACS Infect Dis Date: 2020-01-03 Impact factor: 5.084
Authors: Jason Chien; John H Hwang; Sedtavut Nilaad; Jorge A Masso-Silva; Sae Jeong Ahn; Elisa K McEachern; Alexander Moshensky; Min-Kwang Byun; Laura E Crotty Alexander Journal: Infect Immun Date: 2020-10-19 Impact factor: 3.441
Authors: Mark L Metersky; Timothy R Aksamit; Alan Barker; Radmila Choate; Charles L Daley; Leigh A Daniels; Angela DiMango; Edward Eden; David Griffith; Margaret Johnson; Michael Knowles; Anne E O'Donnell; Kenneth Olivier; Matthias Salathe; Byron Thomashow; Gregory Tino; Gerard Turino; Kevin L Winthrop; David Mannino Journal: Ann Am Thorac Soc Date: 2018-03